A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia

OBJECTIVE: Fludarabine, cyclophosphamide and rituximab (FCR) is the standard regimen for fit patients with untreated CD20-positive chronic lymphocytic leukemia (CLL). However, this combination is unavailable in Japan because rituximab is not approved for CLL. We investigated the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Izutsu, Koji, Kinoshita, Tomohiro, Takizawa, Jun, Fukuhara, Suguru, Yamamoto, Go, Ohashi, Yasuo, Suzumiya, Junji, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937417/
https://www.ncbi.nlm.nih.gov/pubmed/33244584
http://dx.doi.org/10.1093/jjco/hyaa215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937417/
https://www.ncbi.nlm.nih.gov/pubmed/33244584
http://dx.doi.org/10.1093/jjco/hyaa215

Ejemplares similares